U.S. approves new drug addressing type 1 diabetes


LOS ANGELES, Nov. 30 (Xinhua) -- The U.S. Food and Drug Administration (FDA) has recently approved a new therapy that slows the onset of type 1 diabetes.

"It targets one of the root causes of this type of diabetes and can slow the onset of the disease. Better still, the drug could be the herald of a new era in treating the condition," said a podcast of The Economist on Tuesday.

The drug, named Tzield, was authorized by the FDA to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

Tzield binds to certain immune system cells and delays progression to stage 3 type 1 diabetes, according to the FDA. Tzield may deactivate the immune cells that attack insulin-producing cells, while increasing the proportion of cells that help moderate the immune response.

The drug is administered by intravenous infusion once daily for 14 consecutive days.

Article type: free
User access status:
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!
   

Next In World

Roundup: Israeli innovative startups struggle for growth amid inflation
Ukraine to replace defence minister in wartime reshuffle
Jordan closes livestock barns for 14 days after foot-and-mouth disease detected
Chinese investor expresses confidence in Ghanaian market
Tanzania's Zanzibar to host travel exhibition to promote eco-tourism
UN condemns deadly clashes in South Sudan after killing of 27
Cholera cases in eastern Zambia district reach 36
1st LD: One killed after MONUSCO helicopter attacked
Death toll from Tanzania's road accident rises to 21
At least 24 dead in Chile as wildfires expand; foreign help on the way

Others Also Read